ArticleSaudi journal of biological sciences2018

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment.

Zhipeng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.